Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Background: HER2 overexpression/amplification in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) may be associated with resistance to standard-of-care anti-EGFR therapies. Given the lack of comprehensive investigations into this association, we assessed the prognostic or predictive effect of HER2 amplification/overexpression on anti-EGFR treatment outcomes. Methods: A systematic review of MEDLINE, Embase, and Cochrane Library (2001-2021) identified studies evaluating progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) in HER2-positive vs. HER2-negative patients with RAS WT mCRC who received anti-EGFR treatments and whose HER2 status was known. Meta-analyses of proportions (ORR) and hazard ratios (PFS, OS) were performed using random-effect models with pre-specified sensitivity analyses. Results: Five high-quality retrospective cohort studies were included in the meta-analyses representing 594 patients with mCRC. All patients received anti-EGFR treatment, either as monotherapy or in combination with chemotherapy. Meta-analysis of PFS demonstrated a 2.84-fold higher risk of death or progression (95% CI, 1.44-5.60) in patients with HER2-positive (vs. HER2-negative) RAS WT mCRC treated with anti-EGFR regimens. The odds of response to anti-EGFR treatment were 2-fold higher in HER2-negative vs. HER2-positive (odds ratio, 1.96 [95% CI, 1.10-3.48]). Differences in OS were not statistically significant. Sensitivity analyses confirmed the robustness of the base-case estimates. Conclusions: While this study could not account for all confounding factors, in patients with RAS WT mCRC who received anti-EGFR therapy, HER2 overexpression/amplification was associated with worse PFS and ORR and may therefore predict poorer outcomes. HER2 testing is important to inform treatment decisions and could optimize outcomes for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2 is overexpressed in 3–5% of mCRC [31], and HER2 amplification is associated with lower incidence of activating KRAS mutations and occurs more commonly in left-sided CRC tumors.”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [31]
In the citing paper
“HER2 overexpression is a negative predictor associated with reduced efficacy of anti-EGFR therapy [31], and >36% of cetuximab-resistant mCRC with wild-type KRAS, NRAS, BRAF, and PI3K was found to display HER2 overexpression [32].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0109 · Cited by 939
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
A note on graphical presentation of estimated odds ratios from several clinical trials
Galbraith, R. F. (1988) · Statistics in Medicine · doi:10.1002/sim.4780070807 · Cited by 663
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
Yonesaka, K., Zejnullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002442 · Cited by 663
van der Geest, L. G. M., Lam-Boer, J., Koopman, M., Verhoef, C., Elferink, M. A. G., & de Wilt, J. H. W. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9719-0 · Cited by 530
Pietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486
Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., & Bardelli, A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 429
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Valtorta, E., Martino, C., Sartore-Bianchi, A., Penaullt-Llorca, F., Viale, G., Risio, M., Rugge, M., Grigioni, W., Bencardino, K., Lonardi, S., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.98 · Cited by 313
Richman, S. D., Southward, K., Chambers, P., Cross, D., Barrett, J., Hemmings, G., Taylor, M., Wood, H., Hutchins, G., Foster, J. M., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4679 · Cited by 241
Martinelli, E., Ciardiello, D., Martini, G., Troiani, T., Cardone, C., Vitiello, P. P., Normanno, N., Rachiglio, A. M., Maiello, E., Latiano, T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.10.007 · Cited by 225
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Sartore-Bianchi, A., Amatu, A., Porcu, L., Ghezzi, S., Lonardi, S., Leone, F., Bergamo, F., Fenocchio, E., Martinelli, E., Borelli, B., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0785 · Cited by 171
Martin, V, Landi, L., Molinari, F., Fountzilas, G., Geva, R., Riva, A., Saletti, P., De Dosso, S., Spitale, A., Tejpar, S., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.4 · Cited by 156
Raghav, K., Loree, J. M., Morris, J. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Korphaisarn, K., Kee, B., Muranyi, A., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00226 · Cited by 132
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review
Strickler, J. H., Yoshino, T., Graham, R. P., Siena, S., & Bekaii-Saab, T. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.8196 · Cited by 100
Self-citationSome Applications of Radial Plots
Galbraith, R. F. (1994) · Journal of the American Statistical Association · doi:10.1080/01621459.1994.10476864 · Cited by 87
Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
Sawada, K., Nakamura, Y., Yamanaka, T., Kuboki, Y., Yamaguchi, D., Yuki, S., Yoshino, T., Komatsu, Y., Sakamoto, N., Okamoto, W., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.006 · Cited by 85
Raghav, K. P. S., Overman, M. J., Yu, R., Meric-Bernstam, F., Menter, D., Kee, B. K., Muranyi, A., Singh, S., Routbort, M., Chen, K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.3517 · Cited by 74
Takegawa, N., & Yonesaka, K. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.03.001 · Cited by 62
Jeong, J. H., Kim, J., Hong, Y. S., Kim, D., Kim, J. E., Kim, S. Y., Kim, K., Yoon, Y., Kim, D., Chun, S., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.005 · Cited by 49
Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer
Yagisawa, M., Sawada, K., Nakamura, Y., Fujii, S., Yuki, S., Komatsu, Y., Yoshino, T., Sakamoto, N., & Taniguchi, H. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.11.002 · Cited by 35
Khelwatty, S. A., Puvanenthiran, S., Essapen, S., Bagwan, I., Seddon, A. M., & Modjtahedi, H. (2021) · Cancers · doi:10.3390/cancers13040638 · Cited by 17
Schrock, A. B., Lee, J., Sandhu, J. S., Madison, R. W., Cho-Phan, C. D., Snider, J. W., Castellanos, E. H., Venstrom, J. M., & Fakih, M. (2021) · The Oncologist · doi:10.1002/onco.13679 · Cited by 13
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Cutsem, E. V., Wu, C. W., Paulson, A. S., Hubbard, J. L., Coveler, A. L., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.023 · Cited by 7
Self-citationBattaglin, F., Ou, F., Qu, X., Bertagnolli, M. M., Höchster, H. S., Niedzwiecki, D., Goldberg, R. M., Mayer, R. J., Zemla, T., Blanke, C. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4086 · Cited by 4
Bianchi, A. S., Amatu, A., Porcu, L., Ghezzi, S., Lonardi, S., Bergamo, F., Bonazzina, E. F., Mauri, G., Cremolini, C., Ciardiello, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.4_suppl.581 · Cited by 3
Jeong, J. H., Kim, J., Hong, Y. S., Kim, D., Kim, J. E., Kim, S., Kim, K.-P., & Kim, T. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw370.69 · Cited by 2
Poster Abstracts - Academy of Managed Care Pharmacy NEXUS 2021
(2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.10-b.s1 · Cited by 2
Research works printed but not linked: 1
- Kang, 2021, Systematic literature review of HER2 amplification/overexpression in colorectal cancer, J Manag Care Spec Pharm, 27, C6
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
Ciracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 53
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
HER2-targeted therapy in colorectal cancer: a comprehensive review
Benli, Y., Arıkan, H., & Akbulut, Ö. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03887-0 · Cited by 30
Treatment options for HER2-expressing colorectal cancer: updates and recent approvals
Zheng-Lin, B., & Bekaii‐Saab, T. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231225037 · Cited by 27
Self-citation
Metadata
- Authors
- Bekaii-Saab, T. S., Lach, K., Hsu, L.-I., Siadak, M., Stecher, M., Ward, J., Beckerman, R., & Strickler, J. H.
- Affiliations
- Division of Hematology/Oncology, Mayo Clinic , Phoenix, AZ , USA
- Maple Health Group, LLC , New York, NY , USA
- Seagen (United States) (US)
- Duke Medical Center (US)
- Corresponding author
- Strickler, John H
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- Volume
- 28
- Issue
- 10
- Pages
- 885-893
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC10546818
- OpenAlex
- W4384625387
- Cited by
- 36
- References
- 34
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 12 · 2023: 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Oncologist (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Seagen Inc
- Merck Sharp & Dohme Corp
- Merck & Co., Inc
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- HER2 overexpression, HER2 amplification, metastatic colorectal cancer, RAS wild-type, anti-EGFR therapy, progression-free survival, overall response rate, overall survival, predictive biomarkers, HER2 testing, treatment resistance
- MeSH terms
- Panitumumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Rectal Neoplasms, Retrospective Studies, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.